Lumida
/EVH
⌘K
Evolent Health Inc

Evolent Health Inc

EVH
$4.19USD+0.48%+0.02 today

MARKET CAP

473.7M

P/E (TTM)

32.1x

FWD P/E

10.5x

DAY RANGE

$4 – $4

52W RANGE

$2
$10

AI Summary

Stalk
StalkMedium

EVH remains in a Stage 2 advancing regime with a clear higher-highs/higher-lows sequence above rising EMAs, but price is extended into extreme overbought territory and testing the 200-day SMA, with a recent exhaustion candle highlighting near-term momentum fatigue. Immediate entries are unfavorable; we will stalk for a corrective pullback into rising EMAs or the 50-day SMA support zone before initiating long exposure.

  • Q2 revenue $653M soared 31% QoQ; full-year guide upped to $2.6–2.7B
  • Oncology performance suite deal set to add ~$300M annual revenue
  • MER stood at a high 95% in Q2 and may rise further in Q3
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$908.0M$1.4B$2.0B$2.6B$1.9B
YoY %-1.8%+48.9%+45.3%+30.1%-26.6%
P / Sales2.6x1.9x1.9x0.5x0.2x
EV / Sales3.1x2.4x2.5x1.0x1.0x
Gross Profit, Adj.$250.4M$316.6M$460.5M$367.4M$399.9M
YoY %+9.8%+26.4%+45.4%-20.2%+8.9%
Margin %27.6%23.4%23.4%14.4%21.3%
EV / Gross Profit11.3x10.4x10.7x6.9x4.5x
EBITDA, Adj.$43.9M$70.4M$95.3M$104.2M$96.3M
YoY %+11.3%+60.1%+35.5%+9.3%-7.6%
Margin %4.8%5.2%4.9%4.1%5.1%
EV / EBITDA64.6x46.9x51.9x24.4x18.6x
EBIT$-42.4M$3.6M$-63.1M$-40.5M$-425.0M
YoY %+83.8%+108.6%-1832.7%+35.8%-949.8%
Margin %-4.7%0.3%-3.2%-1.6%-22.7%
EV / EBIT-67.0x905.5x-78.3x-62.7x-4.2x
Net Income$-37.6M$-19.2M$-142.3M$-93.5M$-579.4M
YoY %+88.8%+49.0%-642.3%+34.3%-520.0%
Net Margin-4.1%-1.4%-7.2%-3.7%-30.9%
EPS (GAAP)-$0.44-$0.20-$1.28-$0.81-$5.07
YoY %+88.8%+54.5%-540.0%+36.7%-525.9%